Design and Application of Nuclear and Molecular Theragnostic Probes

Abstract

With growing propensity towards personalised medication, the application and impact of molecular theragnostic (or, theranostic) is expected to increase dramatically. Molecular theragnostic is the combination of diagnostics and therapeutics in single targeted molecule. If successful, molecular theragnostic will determine the treatment strategy and therapeutic outcome apart from favourably influencing the time of treatment and comfort of the patient. Recent developments such as [64Cu]Cu‐ATSM for imaging tumor‐hypoxia, 99Y silicate for arthritis, 1⁷⁷Lu‐PSMA‐617 for prostate cancer etc has been discussed in detail in the literature.[1,2] This sectioned review deals in particular with the development of nuclear molecular theragnostic agents. The genesis and design strategies are presented after compiling recent reports.